Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto ™
ConclusionThe therapeutic efficacy of Pluvicto ™ at low radioactive doses can be effectively enhanced by the combination with L19-IL2. Our findings warrant further clinical exploration of this novel combination modality.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Nuclear Medicine | Prostate Cancer | Study | Urology & Nephrology